JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Phosphodiesterase (PDE) assays
Determination of the total PDE3 and PDE4 activities was done using 1 μM cAMP as substrate and 10 μM of either the PDE3 selective inhibitor, Cilostimide, or the PDE4 selective inhibitor, Rolipram.
Cell lines
U937 cells
Preparation method
The solubility of this compound in DMSO is > 13 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting condition
0 ~ 10000 nM; 20 mins
Applications
In U937 cells, Rolipram increased protein kinase A (PKA)-mediated cAMP-response-element-binding protein (CREB) phosphorylation in a dose-dependent manner. In contrast, Rolipram dose-dependently inhibited p38 MAP kinase phosphorylation induced by interferon-γ, with an IC50 value of 294 ± 99 nM.
Animal models
SD rats
Dosage form
300 μg/100 g; i.v.
In SD rats, Rolipram significantly reduced mean arterial pressure. In SD rats treated with lipopolysaccharide and Rolipram, cardiac index significantly increased only at 3 hrs. In addition, Rolipram significantly decreased sinusoidal volumetric flow and increased sinusoidal diameter, which indicated protective effects of Rolipram on sinusoidal microhemodynamics in endotoxemia.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. MacKenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J. 2000 Apr 15;347(Pt 2):571-8.
[2]. Wollborn J, Wunder C, Stix J, Neuhaus W, Bruno RR, Baar W, Flemming S, Roewer N, Schlegel N, Schick MA. Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression. J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):13-23.
